Grifols, S.A Shares Outstanding 2012-2019 | GRFS

Grifols, S.A shares outstanding history from 2012 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Grifols, S.A shares outstanding for the quarter ending September 30, 2019 were M, a 100% decline year-over-year.
  • Grifols, S.A 2018 shares outstanding were 0.685B, a 0.06% increase from 2017.
  • Grifols, S.A 2017 shares outstanding were 0.684B, a 0.15% increase from 2016.
  • Grifols, S.A 2016 shares outstanding were 0.683B, a 0.35% decline from 2015.
Grifols, S.A Annual Shares Outstanding
(Millions of Shares)
2018 685
2017 684
2016 683
2015 686
2014 687
2013 684
2012 685
2011 556
Grifols, S.A Quarterly Shares Outstanding
(Millions of Shares)
Q3 2019
Q2 2019 690
Q2 2018 675
Q2 2017 685
Q1 2017 670
Q4 2016 683
Q3 2016 675
Q2 2016 696
Q1 2016 696
Q4 2015
Q3 2015 683
Q2 2015 682
Q1 2015 676
Q4 2014 691
Q3 2014 692
Q2 2014 692
Q1 2014 691
Q4 2013 714
Q3 2013 674
Q2 2013 673
Q1 2013 663
Q4 2012 791
Q3 2012 670
Q2 2012 693
Q1 2012 675
Q4 2011 912
Q3 2011 572
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $15.656B $5.299B
Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain.
Stock Name Country Market Cap PE Ratio
Takeda Pharmaceutical (TAK) Japan $63.060B 9.97
Zoetis (ZTS) United States $59.275B 35.46
Astellas Pharma (ALPMY) Japan $32.280B 16.12
Eisai (ESALY) Japan $21.727B 41.90
UCB SA (UCBJF) Belgium $15.483B 0.00
Merck (MKGAF) Germany $14.519B 19.81
Neurocrine Biosciences (NBIX) United States $10.185B 480.83
Ono Pharmaceutical (OPHLF) Japan $9.450B 20.20
Ionis Pharmaceuticals (IONS) United States $8.869B 17.96
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $8.449B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $8.366B 10.69
Catalent (CTLT) United States $7.636B 31.07
IPSEN SA ADR (IPSEY) France $7.310B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $6.361B 96.32
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.226B 0.00
Orion OYJ (ORINY) Finland $5.849B 30.12
STADA ARZNEIMI (STDAF) Germany $5.375B 0.00
Hypermarcas (HYPMY) Brazil $5.058B 18.18
FibroGen (FGEN) United States $4.074B 119.72
United Therapeutics (UTHR) United States $3.933B 0.00
Sage Therapeutics (SAGE) United States $3.776B 0.00
Nektar Therapeutics (NKTR) United States $3.742B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.577B 13.07
Evotec AG (EVTCY) Germany $3.562B 58.28
PTC Therapeutics (PTCT) United States $2.974B 0.00
ArQule (ARQL) United States $2.423B 0.00
Heron Therapeutics (HRTX) United States $2.289B 0.00
Zogenix (ZGNX) United States $2.163B 0.00
Xencor (XNCR) United States $2.119B 64.41
Portola Pharmaceuticals (PTLA) United States $2.047B 0.00
Ironwood Pharmaceuticals (IRWD) United States $2.006B 63.95
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.979B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.906B 56.40
Tilray (TLRY) Canada $1.869B 0.00
ChemoCentryx (CCXI) United States $1.823B 0.00
USANA Health Sciences (USNA) United States $1.640B 17.50
Corcept Therapeutics (CORT) United States $1.472B 17.89
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.424B 9.71
Enanta Pharmaceuticals (ENTA) United States $1.314B 30.00
CLINIGEN GP (CLIGF) United Kingdom $1.245B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.240B 0.00
Karyopharm Therapeutics (KPTI) United States $1.052B 0.00
Endo (ENDP) Ireland $1.050B 1.93
Aerie Pharmaceuticals (AERI) United States $1.042B 0.00
Radius Health (RDUS) United States $1.033B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.944B 0.00
Akebia Therapeutics (AKBA) United States $0.760B 0.00
Flexion Therapeutics (FLXN) United States $0.756B 0.00
Collegium Pharmaceutical (COLL) United States $0.702B 0.00
Dermira (DERM) United States $0.692B 0.00
TherapeuticsMD (TXMD) United States $0.624B 0.00
ImmunoGen (IMGN) United States $0.536B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.529B 0.00
Translate Bio (TBIO) United States $0.519B 0.00
Organogenesis Holdings (ORGO) United States $0.464B 0.00
Ardelyx (ARDX) United States $0.461B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.457B 55.38
Aptorum Group (APM) Hong Kong, SAR China $0.441B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.441B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.438B 18.88
Harpoon Therapeutics (HARP) United States $0.419B 0.00
Molecular Templates (MTEM) United States $0.395B 0.00
Indivior (INVVY) United States $0.392B 1.42
OptiNose (OPTN) United States $0.388B 0.00
Recro Pharma (REPH) United States $0.382B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.374B 0.00
DURECT (DRRX) United States $0.373B 0.00
Siga Technologies (SIGA) United States $0.364B 8.31
Lannett Co Inc (LCI) United States $0.363B 4.23
Innate Pharma SA (IPHYF) France $0.336B 0.00
Rafael Holdings (RFL) United States $0.327B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.326B 0.00
Jounce Therapeutics (JNCE) United States $0.306B 4.09
KalVista Pharmaceuticals (KALV) United States $0.302B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.270B 0.00
GlycoMimetics (GLYC) United States $0.258B 0.00
Calithera Biosciences (CALA) United States $0.244B 0.00
Concordia (CXRXF) Canada $0.230B 0.00
Xeris Pharmaceuticals (XERS) United States $0.224B 0.00
Concert Pharmaceuticals (CNCE) United States $0.215B 0.00
Ocular Therapeutix (OCUL) United States $0.195B 0.00
Nature's Sunshine Products (NATR) United States $0.183B 31.53
AcelRx Pharmaceuticals (ACRX) United States $0.180B 0.00
Taiwan Liposome (TLC) Taiwan $0.175B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.171B 0.00
IMV INC (IMV) Canada $0.149B 0.00
MEI Pharma (MEIP) United States $0.149B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.144B 0.00
Redhill Biopharma (RDHL) Israel $0.137B 0.00
Aquestive Therapeutics (AQST) United States $0.132B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.127B 0.00
CannTrust Holdings (CTST) Canada $0.119B 0.00
CV Sciences (CVSI) United States $0.118B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.108B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.096B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.092B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.091B 0.00
CTI BioPharma (CTIC) United States $0.087B 0.00
MediWound (MDWD) Israel $0.084B 0.00
Capnia (SLNO) United States $0.084B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.080B 24.09
Champions Oncology (CSBR) United States $0.079B 0.00
Aclaris Therapeutics (ACRS) United States $0.078B 0.00
Otonomy (OTIC) United States $0.077B 0.00
Neos Therapeutics (NEOS) United States $0.074B 0.00
PolarityTE (PTE) United States $0.070B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.070B 0.00
Nivalis Therapeutics (ALPN) United States $0.068B 0.00
Infinity Pharmaceuticals (INFI) United States $0.066B 0.00
Pharmaxis (PXSLY) Australia $0.065B 0.00
RENEURON GP (RNUGF) United Kingdom $0.062B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.061B 0.00
Natural Alternatives (NAII) United States $0.059B 14.73
Novan (NOVN) United States $0.059B 0.00
Genocea Biosciences (GNCA) United States $0.057B 0.00
Mast Therapeutics (SVRA) United States $0.056B 0.00
Forward Pharma (FWP) Denmark $0.054B 0.00
Medicure (MCUJF) Canada $0.053B 0.00
IntelGenx Technologies (IGXT) Canada $0.051B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.049B 0.00
ElectroCore (ECOR) United States $0.046B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.045B 0.00
SCYNEXIS (SCYX) United States $0.043B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.042B 0.00
Iterum Therapeutics (ITRM) Ireland $0.040B 0.00
Opexa Therapeutics (ACER) United States $0.037B 0.00
Mannatechorporated (MTEX) United States $0.036B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.031B 0.00
Jaguar Animal Health (JAGX) United States $0.029B 0.00
Shineco (TYHT) China $0.027B 0.00
PharmAthene (ALT) United States $0.026B 0.00
Biomerica (BMRA) United States $0.026B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.024B 0.00
ProPhase Labs (PRPH) United States $0.023B 0.00
China SXT Pharmaceuticals (SXTC) China $0.022B 0.00
Bio-Path Holdings (BPTH) United States $0.022B 0.00
Melinta Therapeutics (MLNT) United States $0.021B 0.00
Cardiome Pharma (CORV) Canada $0.020B 0.00
Flex Pharma (SLRX) United States $0.017B 0.00
Regulus Therapeutics (RGLS) United States $0.016B 0.00
Heat Biologics (HTBX) United States $0.015B 0.00
VAXART, INC (VXRT) United States $0.015B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.014B 0.00
Cyanotech (CYAN) United States $0.013B 0.00
Vical (BBI) United States $0.013B 0.00
Lipocine (LPCN) United States $0.009B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.008B 0.00
HANCOCK JAFFE (HJLI) United States $0.008B 0.00
Achieve Life Sciences (ACHV) United States $0.008B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.007B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
RXi Pharmaceuticals (PHIO) United States $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Midatech Pharma (MTP) United Kingdom $0.002B 0.00
Onconova Therapeutics (ONTX) United States $0.002B 0.00
Advanced Accelerator Applications S.A (AAAP) France $0.000B 0.00